Skip to main content
letter
. 2021 Feb 5:zwab010. doi: 10.1093/eurjpc/zwab010

Table 1.

Main characteristics of the included patients at the time of inclusion in our study

Variable Whole cohort (N = 126) Uncontrolled (N = 16) Unstable control (N = 29) Controlled (N = 81) P-value
Baseline characteristics
 Age (years), median [IQ] 66 [58–72] 71 [61–76.5] 69 [66–77] 63 [55–70] 0.003a
 Male, n (%) 47 (37.30) 9 (56.25) 8 (27.59) 30 (37.04) 0.163b
 BMI (kg/m2), median [IQ] 26.31 [23.89–28.76] 28.30 [24.26–31.56] 26.96 [25.00–30.19] 26.03 [23.51–28.09] 0.101a
 Reference systolic BP, mean (SD) 124.78 (9.90) 137.91 (11.14) 128.31 (8.97) 120.93 (6.91) <.0001c
 Reference diastolic BP, mean (SD) 76.19 (8.10) 85.61 (7.31) 76.98 (8.66) 74.04 (6.59) <.0001c
 Smokers, n (%) 27 (21.43) 8 (50.00) 8 (27.59) 11 (13.58) 0.003 b
 Type II diabetes, n (%) 23 (18.25) 2 (12.50) 7 (24.14) 14 (17.28) 0.583b
 Dyslipidaemia, n (%) 47 (37.30) 8 (50) 16 (55.17) 23 (28.40) 0.020b
 Previous cardiovascular events, n (%) 19 (15.08) 3 (18.75) 5 (17.24) 11 (13.58) 0.810d
 CCB, n (%) 52 (57.14) 9 (64.29) 14 (56.00) 29 (55.77) 0.841b
 Beta-blockers, n (%) 31 (34.07) 6 (42.86) 7 (28.00) 18 (34.62) 0.638b
 Diuretics, n (%) 39 (42.86) 7 (50.00) 14 (56.00) 18 (34.62) 0.174b
 ACE inhibitors, n (%) 25 (27.45) 1 (7.14) 9 (36.00) 15 (28.85) 0.145b
 ARB, n (%) 44 (48.35) 10 (71.43) 11 (44.00) 23 (44.23) 0.194d
 Alpha-blockers, n (%) 12 (13.19) 1 (7.14) 6 (24.00) 5 (9.62) 0.217d
 Number of drugs, n (%)
  1 25 (27.47) 1 (7.14) 8 (32.00) 16 (30.77) 0.072d
  2 32 (35.16) 8 (57.14) 4 (16.00) 20 (38.46)
  3 22 (24.18) 3 (21.43) 7 (28.00) 12 (23.08)
  4 12 (13.19) 2 (14.29) 6 (24.00) 4 (7.69)

ACE, angiotensin-converting enzyme; BMI, body mass index; BP, blood pressure; IQ, interquartile range; SD, standard deviation.

a

Kruskal–Wallis.

b

Chi-square test.

c

ANOVA.

d

Fisher test.